Full Press Release Details
Pharma Issues CEO Shareholder Letter Providing Business Update
| Emerging oncology pipeline continues to advance |
| Strong balance sheet with over $60M in cash |
AVIV, July 02, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company
advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, is pleased to provide the following letter
to shareholders from its Chief Executive Officer, Isaac Israel.
our recently closed $35 million financing, we believe we have successfully completed our evolution to an oncology focused biotechnology
company, and wanted to provide our shareholders and other stakeholders with an update on our business and strategic plans. As
of the end of June 2020, we had over $60 million in cash, which we believe positions us well to conduct the two clinical studies
we intend to initiate this year, and provides us with the resources to expand these development programs, as appropriate, as well
as potentially acquire additional promising drug candidates that we may identify to further expand our pipeline.
we continue to support our distribution partners for CONSENSI indicated for the simultaneous treatment of
hypertension and osteoarthritis pain in the U.S. and the Far East. Importantly, following the recent launch of CONSENSI in
the U.S., this drug is expected to begin generating royalty revenue for Kitov this year. With this launch underway, our strategic
focus has shifted to the development of innovative therapeutics to treat cancer patients with significant unmet medical needs.
are focused on building a pipeline of first-in-class oncology assets based on our three core values of Innovation - we have assembled
a team of world-class oncology drug developers, Collaboration - we strive to establish beneficial relationships with our partners
to best progress our mission, and Agility - we are focused on advancing our pipeline as expeditiously as possible. Our emerging
oncology pipeline currently consists of CM24, a monoclonal antibody targeting CEACAM1, a novel immune checkpoint that supports
tumor immune evasion and survival through multiple pathways, in patients with advanced cancer, and NT219, a dual inhibitor, novel
small molecule targeting IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat
addition, with a strong balance sheet that includes no debt, we have the flexibility to enhance our growth through smart acquisitions
and/or in-licensing activity that we may identify in our core focus area of oncology. We expect to identify promising drug candidates
with unique differentiation that have the potential to create exciting new treatment paradigms for the benefit of cancer patients.
Our core objective is to become a recognized leader in the oncology field and to make a significant impact on patients'
important aspect of our strategy is to collaborate with third-parties. As a result of our recent financing activity, our current
balance sheet provides us with the ability to maximize the value of the strategic opportunities that we are pursuing. We look
forward to providing you with further updates on these ongoing activities as events warrant.
would like to provide an update on our current pipeline and CONSENSI :
May 14, 2020, we announced that the positive results of a previously reported Phase 1 trial of CM24 were presented in a poster
presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.
Phase 1 results are encouraging and indicate that CM24 at higher doses warrants further evaluation in a larger clinical study.
Importantly, pharmacokinetic modelling suggests that higher doses of CM24 of up to 20mg/kg administered every two weeks would
be required for target saturation. We look forward to the anticipated initiation of our planned Phase 1/2 clinical trial
to evaluate the combination of CM24 with the PD-1 inhibitor, nivolumab (OPDIVO ), to be conducted in collaboration
with Bristol Myers Squibb, which we expect to initiate in the second half of this year. In order to maximize the potential of
the trial to demonstrate a strong efficacy signal, we intend to include expansion cohorts that will follow the dose escalating
phase: an expansion cohort in non-small cell lung cancer patients, and an additional expansion cohort in pancreatic cancer patients.
This new arm of the trial in pancreatic cancer patients is designed to evaluate the CEACAM1/PD-1 combination in addition to standard
of care chemotherapy.
May 22, 2020, we announced that the U.S. Food and Drug Administration had accepted our Investigational New Drug application to
conduct a Phase 1/2 clinical trial of NT219. The study is designed to evaluate NT219 as a monotherapy treatment for advanced solid
tumors and in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the treatment
of recurrent or metastatic solid tumors and head and neck cancer or colorectal adenocarcinoma.
on the encouraging pre-clinical data generated in various studies with NT219, as both monotherapy and in combination with cetuximab,
we believe this promising drug candidate has the potential to be a safe and effective therapy for multiple hard-to-treat cancers.
In addition to U.S. clinical sites, and in order to mitigate a potential COVID-19 pandemic-related slowdown in patient recruitment
into the study, we are also including additional clinical sites in Canada.
primary objectives of the open-label Phase 1/2 trial are to evaluate safety, assess pharmacokinetics, identify the appropriate
dose to be studied in the Phase 2 portion, and establish preliminary efficacy of NT219. The Phase 1 portion of the study will
encompass a dose escalation evaluation of NT219 monotherapy administered in patients with refractory advanced solid tumors. A
second cohort of patients, with either recurrent or metastatic squamous cell carcinoma of the head and neck or colorectal adenocarcinoma,
will be dosed with NT219, dose escalated, in combination with cetuximab. Upon completion of the Phase 1 monotherapy and combination
dose escalation portion of the trial, we plan to commence the expansion Phase 2 components of the study at the recommended Phase
2 dose of NT219 in combination with cetuximab. In addition, based on the data obtained in the Phase 1 monotherapy portion, we
intend to pursue an expansion Phase 2 study in a yet to be defined indication for NT219 as monotherapy.
principal investigator of the Phase 1/2 study is Dr. Ezra Cohen, Chief, Division of Hematology-Oncology at the University of California
San Diego, and a distinguished key opinion leader. We expect to activate up to eight sites in the U.S. and Canada over the next
few months and that our first clinical site will be initiated shortly.
May 20, 2020, we announced the U.S. commercial launch of CONSENSI , a fixed-dose combination of celecoxib and amlodipine
besylate, designed for the simultaneous treatment of hypertension and osteoarthritis pain. CONSENSI is being
sold in the U.S. by Burke Therapeutics, the marketing partner of Kitov's U.S. distributor, Coeptis Pharmaceuticals.
Therapeutics' sales team is growing steadily, and is expected to soon include about 50 sales representatives, with plans
to increase this number further. We believe the team is highly-motivated to introduce this once-a-day treatment for hypertension
and osteoarthritis pain in the U.S. market. In addition, we believe Burke is taking the necessary actions to overcome the short-term
challenges imposed by the COVID-19 pandemic and we look forward to sales beginning to ramp up in the next few months, which will
result in royalty revenue to us of 20% of sales, pursuant to our marketing and distribution agreement with Coeptis. According
to the agreement for CONSENSI , Kitov is eligible to receive up to $99.5 million in milestone and reimbursement
payments, in addition to royalties. We expect to receive aggregate milestone and royalty revenues of between $28 million and $36
million from 2020 through 2022.
summary, we look forward to further advancing our commercial and clinical activities by leveraging our strong cash position. Our
current cash runway is expected to support our currently planned activities into at least 2024, beyond multiple anticipated clinical
milestones, and we believe we are well-funded to execute our strategic plans.
thank you for your continued support of Kitov.
you and yours good health,
Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome
tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer. Kitov's oncology
pipeline includes NT-219 and CM-24. NT-219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and
STAT3. Kitov is currently advancing NT-219 as a monotherapy treatment of advanced solid tumors and in combination with cetuximab
for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer (SCCHN) in a planned phase 1/2 study.
CM-24 is a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival through
multiple pathways. Kitov plans to advance CM-24 as a combination therapy with anti-PD1 checkpoint inhibitors in selected cancer
indications in a phase 1 study followed by a phase 2 for the treatment of non-small cell lung cancer NSCLC and pancreatic cancer.
Kitov has entered into a clinical collaboration agreement with Bristol Myers Squibb Company for the planned phase 1/2 clinical
trials to evaluate the combination of CM-24 with the PD-1 inhibitor nivolumab (Opdivo ). Kitov is also the owner of Consensi ,
a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension
that was approved by the FDA for marketing in the U.S. Consensi is being sold in the U.S. by Burke Therapeutics, the marketing
partner of Kitov's U.S. distributor, Coeptis Pharmaceuticals. Kitov has also partnered to commercialize Consensi in China
and South Korea. The company is headquartered in Tel Aviv, Israel. For more information, please visit http://www.kitovpharma.com.
Statements and Kitov's Safe Harbor Statement
statements in this press release that are forward-looking and not statements of historical fact are forwardlooking statements
within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project",
"forecast", "continue" or "anticipate" or their negatives or variations of these words or
other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place
undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements
reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions,
involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause
our actual results, performance or achievements to be significantly different from any future results, performance or achievements